what are the Recommendation for Pharmacological Prevention of SCD
References that support the recommendation are summarized in
Online Data Supplement 10.?
In patients with HFrEF (LVEF ?40%), treatment with a beta blocker, a mineralocorticoid receptor antagonist and either an angiotensin-converting enzyme inhibitor, an angiotensin-receptor blocker, or an angiotensin receptor-neprilysin inhibitor is recommended to reduce SCD and all-cause mortality.S